Quantity of eligible patients: CDEC discussed the uncertainty in the number of patients with reasonably critical to critical hemophilia B in Canada qualified for etranacogene dezaparvovec. Clinical specialists consulted by CADTH indicated that some patients who will be labeled as possessing mild or average disorder could have a extreme bleeding https://keytrudacost83714.luwebs.com/36793678/how-hemgenix-can-save-you-time-stress-and-money